Andrew has over 30 years’ experience in co-founding, building and leading biotechnology companies in Europe and the USA. He has served in CXO and board positions in 14 companies including Cantab, Signature, Ionix, Hexagen, Syntaxin, Synosia, Kymab, Bicycle and PredictImmune. He also has 7 years’ experience in venture capital with Abingworth and Syncona. He has worked with investors to create shareholder liquidity through mergers, acquisitions and public offerings. Andrew has a BSc in Chemistry, University of East Anglia and Diploma in Marketing, Chartered Institute of Marketing.
Professor Itzhaki has over 20 years’ experience in leading academic research in the field of protein structure and engineering, including protein stability and folding, tandem-repeat proteins and structural biology of the ubiquitin proteasome pathways. Professor Itzhaki has a BA in Chemistry, University of Oxford, and PhD in Biochemistry, University of Cambridge.
Kevin has over 30 years’ experience in pharmaceutical discovery and development in the fields of oncology, inflammation, immunology, cardiovascular and infectious diseases. He has served in research leadership positions in 9 international biotechnology companies including Biogen, Domantis, F-Star and Tusk Therapeutics, where he served as Chief Development Officer until its acquisition in 2018 by Roche. Kevin holds a BSc in biological sciences and a PhD in Immunology from the University of London.
Laura has over 15 years’ experience working in a variety of administrative and executive support roles across various sectors in the Cambridge area. These include large organisations such as the Cambridgeshire Country Council, to small start-up companies. Most recently Laura was Personal Assistant and Team Administrator at Kymab, where she supported the company to grow from a tiny start-up to the maturing company it is now.